Gene Mutations as Emerging Biomarkers and Therapeutic Targets for Relapsed Acute Myeloid Leukemia

被引：12

作者：

Aziz, Habsah ^{[1
]}

Ping, Chow Y. ^{[1
]}

Alias, Hamidah ^{[2
]}

Ab Mutalib, Nurul-Syakima ^{[1
]}

Jamal, Rahman ^{[1
]}

机构：

[1] Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst, Kuala Lumpur, Malaysia

[2] Univ Kebangsaan Malaysia, Dept Paediat, Fac Med, Kuala Lumpur, Malaysia

来源：

FRONTIERS IN PHARMACOLOGY | 2017年 / 8卷

关键词：

acute myeloid leukemia; mutation; adult; childhood; relapse; biomarker; ACUTE MYELOGENOUS LEUKEMIA; INTERNAL TANDEM DUPLICATION; IDH2; MUTATIONS; DNMT3A MUTATIONS; TET2; PROGNOSTIC-SIGNIFICANCE; SOMATIC MUTATIONS; KINASE INHIBITOR; CLONAL EVOLUTION; CEBPA MUTATIONS;

D O I：

10.3389/fphar.2017.00897

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

It is believed that there are key differences in the genomic profile between adult and childhood acute myeloid leukemia (AML). Relapse is the significant contributor of mortality in patients with AML and remains as the leading cause of cancer death among children, posing great challenges in the treatment of AML. The knowledge about the genomic lesions in childhood AML is still premature as most genomic events defined in children were derived from adult cohorts. However, the emerging technologies of next generation sequencing have narrowed the gap of knowledge in the biology of AML by the detection of gene mutations for each sub-type which have led to the improvement in terms of prognostication as well as the use of targeted therapies. In this review, we describe the recent understanding of the genomic landscape including the prevalence of mutation, prognostic impact, and targeted therapies that will provide an insight into the pathogenesis of AML relapse in both adult and childhood cases.

引用

页数：14

共 134 条

[1]

Ab Manan A., 2016, MALAYSIA CANC STAT D

[2] Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value [J].

Abbas, Saman ;

Lugthart, Sanne ;

Kavelaars, Francois G. ;

Schelen, Anita ;

Koenders, Jasper E. ;

Zeilemaker, Annelieke ;

van Putten, Wim J. L. ;

Rijneveld, Anita W. ;

Lowenberg, Bob ;

Valk, Peter J. M. .

BLOOD, 2010, 116 (12) :2122-2126

[3] Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers [J].

Adjei, Alex A. ;

Cohen, Roger B. ;

Franklin, Wilbur ;

Morris, Clive ;

Wilson, David ;

Molina, Julian R. ;

Hanson, Lorelei J. ;

Gore, Lia ;

Chow, Laura ;

Leong, Stephen ;

Maloney, Lara ;

Gordon, Gilad ;

Simmons, Heidi ;

Marlow, Allison ;

Litwiler, Kevin ;

Brown, Suzy ;

Poch, Gregory ;

Kane, Katie ;

Haney, Jerry ;

Eckhardt, S. Gail .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) :2139-2146

[4] Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype [J].

Ahn, Jae-Sook ;

Kim, Hyeoung-Joon ;

Kim, Yeo-Kyeoung ;

Jung, Sung-Hoon ;

Yang, Deok-Hwan ;

Lee, Je-Jung ;

Lee, Il-Kwon ;

Kim, Nan Young ;

Minden, Mark D. ;

Jung, Chul Won ;

Jang, Jun-Ho ;

Kim, Hee Je ;

Moon, Joon Ho ;

Sohn, Sang Kyun ;

Won, Jong-Ho ;

Kim, Sung-Hyun ;

Kim, Namshin ;

Yoshida, Kenichi ;

Ogawa, Seishi ;

Kim, Dennis Dong Hwan .

HAEMATOLOGICA, 2015, 100 (09) :E351-E353

[5] Frequent Coexistence of RAS Mutations in RUNX1-Mutated Acute Myeloid Leukemia in Arab Asian Children [J].

Al-Kzayer, Lika'a Fasih Y. ;

Sakashita, Kazuo ;

Al-Jadiry, Mazin Faisal ;

Al-Hadad, Salma Abbas ;

Uyen, Le T. N. ;

Liu, Tingting ;

Matsuda, Kazuyuki ;

Abdulkadhim, Jaafar M. H. ;

Al-Shujairi, Tariq Abadi ;

Matti, Zead Ismael I. K. ;

Hasan, Janan Ghalib ;

Al-Abdullah, Hussam M. Salih ;

Inoshita, Toshi ;

Kamata, Minoru ;

Sughayer, Maher A. ;

Madanat, Faris F. ;

Koike, Kenichi .

PEDIATRIC BLOOD & CANCER, 2014, 61 (11) :1980-1985

[6] Treatment With FLT3 Inhibitor in Patients With FLT3-Mutated Acute Myeloid Leukemia Is Associated With Development of Secondary FLT3-Tyrosine Kinase Domain Mutations [J].

Alvarado, Yesid ;

Kantarjian, Hagop M. ;

Luthra, Rajyalakshmi ;

Ravandi, Farhad ;

Borthakur, Gautam ;

Garcia-Manero, Guillermo ;

Konopleva, Marina ;

Estrov, Zeev ;

Andreeff, Michael ;

Cortes, Jorge E. .

CANCER, 2014, 120 (14) :2142-2149

[7] IDH1 and IDH2 mutations in pediatric acute leukemia [J].

Andersson, A. K. ;

Miller, D. W. ;

Lynch, J. A. ;

Lemoff, A. S. ;

Cai, Z. ;

Pounds, S. B. ;

Radtke, I. ;

Yan, B. ;

Schuetz, J. D. ;

Rubnitz, J. E. ;

Ribeiro, R. C. ;

Raimondi, S. C. ;

Zhang, J. ;

Mullighan, C. G. ;

Shurtleff, S. A. ;

Schulman, B. A. ;

Downing, J. R. .

LEUKEMIA, 2011, 25 (10) :1570-1577

[8]

[Anonymous], 2014, FRONT ONCOL

[9] Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients [J].

Aref, Salah ;

Areida, El Sayed Kamel ;

Aaal, Mohamed Fathy Abdel ;

Adam, Ola Mohamed ;

El-Ghonemy, Mohamed Sabry ;

El-Baiomy, Mohamed Ali ;

Abou Zeid, Tarek .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (09) :550-555

[10] Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial [J].

Aslanyan, Mariam G. ;

Kroeze, Leonie I. ;

Langemeijer, Saskia M. C. ;

Koorenhof-Scheele, Theresia N. ;

Massop, Marion ;

van Hoogen, Patricia ;

Stevens-Linders, Ellen ;

van de Locht, Louis T. ;

Tonnissen, Evelyn ;

van der Heijden, Adrian ;

da Silva-Coelho, Pedro ;

Cilloni, Daniela ;

Saglio, Giuseppe ;

Marie, Jean-Pierre ;

Tang, Ruoping ;

Labar, Boris ;

Amadori, Sergio ;

Muus, Petra ;

Willemze, Roel ;

Marijt, Erik W. A. ;

de Witte, Theo ;

van der Reijden, Bert A. ;

Suciu, Stefan ;

Jansen, Joop H. .

ANNALS OF HEMATOLOGY, 2014, 93 (08) :1401-1412

← 1 2 3 4 5 6 7 8 9 10 →